---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-127783"
form_type: "8-K"
ticker: "LQDA"
cik: "0001819576"
company_name: "Liquidia Corp"
filed_at: "2023-12-20T23:59:59+00:00"
generated_at: "2026-06-07T09:58:59.312774+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Liquidia wins Federal Circuit ruling affirming invalidation of United Therapeutics' '793 patent

## Summary
- Federal Circuit upheld PTAB decision finding all claims of U.S. Patent No. 10,716,793 unpatentable.
- Liquidia will immediately seek to set aside the District Court injunction and pursue final FDA approval of YUTREPIA.
- FDA PDUFA goal date for PH-ILD indication is January 24, 2024.
- CEO Roger Jeffs stated company now has rulings that YUTREPIA does not infringe any valid claim in three initially asserted patents.
- Liquidia will also seek dismissal of related claims in second Hatch-Waxman lawsuit and defend against new '327 patent allegations.

## SEC filing metadata
- accession: 0001104659-23-127783
- form_type: 8-K
- ticker: LQDA
- cik: 0001819576
- company_name: Liquidia Corp
- filed_at: 2023-12-20T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819576/000110465923127783/0001104659-23-127783-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819576/000110465923127783/tm2333396d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-127783
- JSON: https://secwatch.observer/filing/0001104659-23-127783.json
- Plain text: https://secwatch.observer/filing/0001104659-23-127783.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.